GlassScriptPhysician profile
Afshan Khan
NPI 1427547736
$1,688.43
in general payments reported to CMS, 2019-2025
21 companies · $246 in 2025
The $246 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $11.87 · 2021: $14.08 · 2022: $345 · 2023: $601 · 2024: $471 · 2025: $246.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,318.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,317.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $463.41 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $193.09 | 2022-2025 | Ozempic, Rybelsus |
| Exact Sciences Corporation | $190.80 | 2023-2025 | Cologuard Collection Kit |
| Abbvie INC. | $134.56 | 2022-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $132.99 | 2022-2024 | |
| Neos Therapeutics, LP | $81.03 | 2020-2023 | Adzenys Xr-Odt |
| Lilly USA, LLC | $75.64 | 2022-2023 | Mounjaro |
| Amgen INC. | $73.10 | 2024-2025 | Repatha, Otezla, Otezla |
| Mylan Specialty L.P. | $59.84 | 2023 | Yupelri |
| Pfizer INC. | $48.12 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.60 | 2025 | Ofev |
| Actelion Pharmaceuticals US, INC. | $28.16 | 2023 | Uptravi, Opsumit |
| Glaxosmithkline, LLC. | $26.24 | 2022-2023 | Arexvy, Shingrix |
| Astellas Pharma US INC | $24.20 | 2025 | Veozah |
| Corcept Therapeutics | $23.97 | 2025 | Korlym |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $19.32 | 2022 | |
| Ethicon US, LLC | $18.60 | 2022 | |
| Allergan, INC. | $18.33 | 2022 | |
| Janssen Pharmaceuticals, INC | $16.54 | 2023 | Xarelto |
| Tms Neurohealth Centers INC. | $14.84 | 2025 | Tms Neurohealth Centers INC. |
| Axsome Therapeutics, INC. | $14.05 | 2025 | Symbravo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Afshan Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.